PHILADELPHIA, Oct. 1 /PRNewswire/ -- Premier Research Group Limited, the international pharmaceutical and medical device services company, announces the promotion of its current Chief Operating Officer, Troy W. McCall, Ph.D. to Chief Executive Officer. The appointment is part of the company's longstanding succession plan to support current CEO Dr. Simon Yaxley's desire to transition to an advisory role with the company's Board of Directors as Deputy Chairman.
Michael Barry, Non-Executive Chairman of the Board of Premier Research Group Limited, said, "On behalf of the Board, I would like to thank Dr. Yaxley for his efforts, commitment to excellence, and vision as CEO and Co-founder of Premier Research. Dr. McCall's commitment, drive, and deep understanding of the business make him the ideal successor to ensure that Premier Research maintains its outstanding track record of growth and customer service."
Dr. McCall's move into the CEO role is effective immediately and follows on the heels of nearly three years with the company as COO where he has led the successful integration of four acquisitions, established a global organization, and achieved year on year organic growth in excess of 20%. During Dr. McCall's tenure as COO, the company has initiated support of medical device trials in the U.S., launched a Functional Sourcing group, expanded the company's clinical research sites, and completed the company's first ever NDA submission on behalf a sponsor. Dr. McCall's leadership has firmly established Premier Research as a high quality, full-service, global CRO.
Dr. Simon Yaxley, Deputy Chairman, commented, "It is exciting and rewarding to have Troy stepping into the CEO role. This is what we have been working together towards and he deserves the recognition. I can think of no one more suited to continue to grow this successful company we, and many others, have worked hard to create. I also look forward to my continued involvement in the business as we continue to grow both organically as well as through acquisition."
Dr. McCall stated, "When I joined Premier Research, it was with the primary goal for the company to become the CRO of choice for global pharmaceutical and biotechnology companies. I am proud to say that we have completed several important milestones, and we are well on our way. This would not have been possible without the efforts and contributions of everyone in the organization. I am grateful for those efforts and look forward to continuing to exceed our client's expectations though our focus on operational excellence and unparalleled customer service."
About Premier Research
Premier Research is a leading global solutions-driven CRO committed to therapeutic focus and operational expertise to deliver clinical trial services of the highest quality for biopharmaceutical and medical device companies. They are leaders in clinical research for analgesia, neuroscience, oncology, and infectious disease and have a wealth of experience in medical device and pediatric research.
Premier Research has 30 offices and operates in more than 30 countries across North America and Europe employing more 1,200 clinical professionals dedicated first and foremost to fulfilling each client's requirements in a timely, accurate, and cost-effective manner. This includes a strong international network of monitors and project management professionals combined with regulatory, data management, statistical, scientific and medical experts, and staff at our well-established network of dedicated clinical sites.
SOURCE Premier Research Group Limited
|SOURCE Premier Research Group Limited|
Copyright©2009 PR Newswire.
All rights reserved